Roche Reports Phase 3 Results for CMV Prevention in Transplant Recipients

Roche today announced Phase 3 trial results evaluating antiviral prophylaxis strategies for cytomegalovirus (CMV) prevention in solid organ transplant recipients. The trial compared different prophylaxis durations and strategies, demonstrating that extended prophylaxis significantly reduced CMV disease incidence compared to standard prophylaxis duration.